Bio Bridge Science (CE) (USOTC:BGES)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Bio Bridge Science (CE) Charts. Click Here for more Bio Bridge Science (CE) Charts.](/p.php?pid=staticchart&s=NO%5EBGES&p=8&t=15)
Bio-Bridge Science, Inc. (OTCBB: BGES)
a developer of vaccines with broad preventative and therapeutic
applications, is pleased to announce that Mr. Trevor Roy and Mr. Anthony
Cheung have been named to the Company’s board
of directors.
Both Mr. Roy and Mr. Cheung bring to Bio-Bridge abundant successful
business experience and numerous international relationships. Their
addition to the board of directors will help Bio-Bridge quickly reach
strategic goals in the pursuit to develop vaccines to treat and improve
human health.
"On behalf of Bio-Bridge Science, we welcome Mr. Roy and Mr. Cheung to
the board of directors. I am confident that they will contribute greatly
to our goal to become a leading international vaccine development and
production company," said Dr. Liang Qiao, Chairman and CEO of Bio-Bridge
Science, Inc.
Mr. Roy was a graduate of the University of Sydney. His initial career
was in education where he was a teacher and administrator at both high
school and tertiary levels. Then in a business career spanning 30 years,
Mr. Roy, with his investment and management experience, both in his home
country of Australia and internationally, has been in a wide range of
industries including rural/agricultural, theatrical, marketing and
promotions, food manufacturing and distribution, medical, and telephony
and communications. For the past 18 years, Mr. Roy has been CEO (now
Chairman) of the Creata Group of Companies and has been instrumental in
establishing its business as a global provider of marketing and
promotional programs in 18 offices throughout 12 countries.
Mr. Cheung's early career was in finance, accounting and auditing with
John B. P. Byrne & Co., now Grant Thornton in Hong Kong. This formed the
foundation of a successful business management and investment career
over 25 years that now includes: ownership of manufacturing facilities
in Hong Kong and China (Dongguan) with an excess of 10,000 employees
producing over 200 million consumer products annually; ownership of a
Class 2 hospital in China (Fujian); and (commercial) real estate
investments and developments in Hong Kong, China and the United States.
Forward Looking Statements:
This press release contains forward-looking statements as defined by the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements include statements concerning plans, objectives, goals,
strategies, future events or performance, and underlying assumptions and
other statements that are other than statements of historical facts.
These statements are subject to uncertainties and risks including, but
not limited to, product and service demand and acceptance, changes in
technology, economic conditions, the impact of competition and pricing,
government regulation, and other risks defined in this document and in
statements filed from time to time with the Securities and Exchange
Commission. All such forward-looking statements, whether written or
oral, and whether made by or on behalf of the company, are expressly
qualified by these cautionary statements and any other cautionary
statements which may accompany the forward-looking statements. In
addition, the company disclaims any obligation to update any
forward-looking statements to reflect events or circumstances after the
date hereof. Please refer to SEC filings for additional information.